| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.
|
J Biol Chem
|
2005
|
3.53
|
|
2
|
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability.
|
Pharmacogenet Genomics
|
2005
|
2.68
|
|
3
|
Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.
|
Proc Natl Acad Sci U S A
|
2007
|
2.62
|
|
4
|
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.
|
Blood
|
2008
|
2.18
|
|
5
|
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance.
|
Cancer Res
|
2004
|
2.10
|
|
6
|
Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer.
|
Mol Pharmacol
|
2005
|
1.73
|
|
7
|
Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells.
|
Cancer Lett
|
2005
|
1.63
|
|
8
|
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance.
|
Cancer Res
|
2005
|
1.58
|
|
9
|
In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
|
J Pharmacol Exp Ther
|
2005
|
1.54
|
|
10
|
Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves.
|
Biotechniques
|
2003
|
1.53
|
|
11
|
Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues.
|
Pharmacogenet Genomics
|
2008
|
1.51
|
|
12
|
Allelic mRNA expression of X-linked monoamine oxidase a (MAOA) in human brain: dissection of epigenetic and genetic factors.
|
Hum Mol Genet
|
2006
|
1.41
|
|
13
|
Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions.
|
J Pharmacol Exp Ther
|
2004
|
1.32
|
|
14
|
Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
|
J Pharmacol Exp Ther
|
2003
|
1.32
|
|
15
|
Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues.
|
Pharmacogenet Genomics
|
2006
|
1.27
|
|
16
|
Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1).
|
AAPS J
|
2006
|
1.24
|
|
17
|
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.
|
J Pharmacol Exp Ther
|
2005
|
1.04
|
|
18
|
Growth factor signaling and resistance to cancer chemotherapy.
|
Curr Top Med Chem
|
2004
|
1.03
|
|
19
|
Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
|
J Pharmacol Exp Ther
|
2005
|
0.99
|
|
20
|
Messenger RNA expression of transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared to human intestines.
|
Pharm Res
|
2003
|
0.99
|
|
21
|
Calmodulin binding to peptides derived from the i3 loop of muscarinic receptors.
|
Pharm Res
|
2006
|
0.95
|
|
22
|
Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin.
|
Mol Pharmacol
|
2007
|
0.94
|
|
23
|
Genetic variants of the human dipeptide transporter PEPT1.
|
J Pharmacol Exp Ther
|
2005
|
0.91
|
|
24
|
Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist.
|
J Pharmacol Exp Ther
|
2002
|
0.89
|
|
25
|
Functional screening of G protein-coupled receptors by measuring intracellular calcium with a fluorescence microplate reader.
|
J Biomol Screen
|
2002
|
0.88
|
|
26
|
Monitoring intracellular pH changes in response to osmotic stress and membrane transport activity using 5-chloromethylfluorescein.
|
AAPS PharmSci
|
2002
|
0.87
|
|
27
|
Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome.
|
AAPS PharmSci
|
2003
|
0.85
|
|
28
|
Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays.
|
Eur J Pharm Sci
|
2004
|
0.85
|
|
29
|
Functional characterization of the peptide transporter PEPT2 in primary cultures of human upper airway epithelium.
|
Am J Respir Cell Mol Biol
|
2004
|
0.85
|
|
30
|
Prediction of anticancer drug potency from expression of genes involved in growth factor signaling.
|
Pharm Res
|
2006
|
0.84
|
|
31
|
Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach.
|
Drug Discov Today
|
2003
|
0.83
|
|
32
|
A semiautomated approach to gene discovery through expressed sequence tag data mining: discovery of new human transporter genes.
|
AAPS PharmSci
|
2003
|
0.82
|
|
33
|
Serum response factor activation by muscarinic receptors via RhoA. Novel pathway specific to M1 subtype involving calmodulin, calcineurin, and Pyk2.
|
J Biol Chem
|
2002
|
0.81
|
|
34
|
Chemogenomic analysis identifies geldanamycins as substrates and inhibitors of ABCB1.
|
Pharm Res
|
2007
|
0.81
|
|
35
|
Calmodulin interaction with peptides from G-protein coupled receptors measured with S-Tag labeling.
|
Biochem Biophys Res Commun
|
2005
|
0.81
|
|
36
|
Design, synthesis, and biological evaluation of non-peptidic ligands at the Xenopus laevis skin-melanocortin receptor.
|
Eur J Med Chem
|
2003
|
0.79
|
|
37
|
Pharmacogenomics approach reveals MRP1 (ABCC1)-mediated resistance to geldanamycins.
|
Pharm Res
|
2008
|
0.79
|
|
38
|
Differential effects of mu-opioid receptor ligands on Ca(2+) signaling.
|
J Pharmacol Exp Ther
|
2002
|
0.79
|
|
39
|
6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice.
|
Life Sci
|
2009
|
0.77
|